Statements (64)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Clinical_Trials
|
| gptkbp:aims_to_improve |
overall survival
|
| gptkbp:analyzes |
adverse events
|
| gptkbp:business_model |
institutional review boards
|
| gptkbp:collaborated_with |
research institutions
research projects |
| gptkbp:concluded_on |
as of 2023
|
| gptkbp:conducted |
gptkb:guidelines
informed consent multiple countries clinical settings oncologists clinical trial networks clinical oversight |
| gptkbp:evaluates |
quality of life
|
| gptkbp:focuses_on |
gptkb:Oncology
|
| gptkbp:has_endpoints |
primary and secondary
|
| https://www.w3.org/2000/01/rdf-schema#label |
TH3 RESA trial
|
| gptkbp:includes |
placebo group
|
| gptkbp:investigates |
treatment efficacy
|
| gptkbp:involves |
patients with relapsed multiple myeloma
|
| gptkbp:is_analyzed_in |
treatment adherence
patient demographics long-term effects safety profiles |
| gptkbp:is_collaborative_with |
international organizations
between institutions |
| gptkbp:is_compared_to |
treatment regimens
|
| gptkbp:is_designed_to |
improve treatment outcomes
|
| gptkbp:is_documented_in |
clinical trial registries
clinical trial databases |
| gptkbp:is_evaluated_by |
peer review process
treatment response efficacy and safety |
| gptkbp:is_focused_on |
patient outcomes
treatment pathways treatment innovation |
| gptkbp:is_funded_by |
government grants
|
| gptkbp:is_informed_by |
previous studies
|
| gptkbp:is_monitored_by |
gptkb:data_safety_monitoring_board
|
| gptkbp:is_part_of |
clinical research
drug development process |
| gptkbp:is_related_to |
novel therapies
FDA approval process |
| gptkbp:is_reviewed_by |
scientific committees
|
| gptkbp:is_supported_by |
patient advocacy groups
scientific research grants pharmaceutical research funding |
| gptkbp:is_utilized_for |
regulatory submissions
|
| gptkbp:measures |
response rates
|
| gptkbp:presented_by |
medical conferences
|
| gptkbp:published_by |
clinical trial registries
|
| gptkbp:recruitment |
adult participants
|
| gptkbp:reported_by |
gptkb:literature
regulatory agencies clinical researchers clinical trial reports |
| gptkbp:result |
medical journals
|
| gptkbp:sponsored_by |
pharmaceutical companies
|
| gptkbp:uses |
randomized controlled design
|
| gptkbp:utilizes |
biomarkers
|
| gptkbp:bfsParent |
gptkb:Trastuzumab_emtansine
gptkb:ado-trastuzumab_emtansine |
| gptkbp:bfsLayer |
7
|